Delving into the Latest Updates on ALG-097111 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

SARS-CoV-2 3CLpro

Mechanism

SARS-CoV-2 3CLpro inhibitors(SARS-CoV-2-3C-like-proteinase inhibitors)

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

COVID-19

Inactive Indication-

Originator Organization

Rega Institute for Medical Research

Aligos Therapeutics, Inc.

Centre for Drug Design & Discovery

Active Organization

Aligos Therapeutics, Inc.

CISTIM

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Author: Chaltin, Patrick ; Neyts, Johan ; Foo, Caroline S ; Bardiot, Dorothée ; Jekle, Andreas ; Abdelnabi, Rana ; Chanda, Sushmita ; Jochmans, Dirk ; Vandyck, Koen ; Boland, Sandro ; Symons, Julian A ; Blatt, Lawrence M ; Gupta, Kusum ; Raboisson, Pierre ; Serebryany, Vladimir ; Marchand, Arnaud ; Dejonghe, Steven ; Vangeel, Laura ; Stoycheva, Antitsa ; Beigelman, Leonid ; Liu, Cheng ; Deval, Jerome ; Ren, Suping ; Misner, Dinah

There is an urgent need for antivirals targeting the SARS-CoV-2 virus to fight the current COVID-19 pandemic. The SARS-CoV-2 main protease (3CLpro) represents a promising target for antiviral therapy. The lack of selectivity for some of the reported 3CLpro inhibitors, specifically versus cathepsin L, raises potential safety and efficacy concerns. ALG-097111 potently inhibited SARS-CoV-2 3CLpro (IC₅₀ = 7 nM) without affecting the activity of human cathepsin L (IC₅₀ > 10 μM). When ALG-097111 was dosed in hamsters challenged with SARS-CoV-2, a robust and significant 3.5 log₁₀ (RNA copies/mg) reduction of the viral RNA copies and 3.7 log₁₀ (TCID₅₀/mg) reduction in the infectious virus titers in the lungs was observed. These results provide the first in vivo validation for the SARS-CoV-2 3CLpro as a promising therapeutic target for selective small molecule inhibitors.

100 Deals associated with ALG-097111

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Preclinical	US	Aligos Therapeutics, Inc.	01 May 2021
COVID-19	Preclinical	BE	Aligos Therapeutics, Inc.	01 May 2021
COVID-19	Preclinical	BE	CISTIM	01 May 2021